Another thought is that if DNDN includes p-11 efficacy data and that data is good, then IMPACT becomes utterly meaningless. I think the FDA could tell DNDN to scrap IMPACT if p-11 is good. That could be another reason why DNDN is submitting p-11 efficacy. Scrapping IMPACT would save DNDN a lot of money for sure.
EagleEye is a nice guy but has a long history of completely unrealistic expectations. Look back a little over a year for what he was saying about NDA filing, ... . Also note that he does not understand anything at all about how drug trials work - e.g. saying that the FDA would "tell DNDN to scrap IMPACT if P-11 is good".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.